Issuer directory · Biotechnology · page 7
Biotechnology: issuers 601 to 700 of 832.
Ranked by the amount reported sold on the newest Form D. Page 1 holds the largest raises in the group.
| Issuer | Reported sold | Investors | Exemption | Newest notice | Filings | Platform |
|---|---|---|---|---|---|---|
| Trefoil Therapeutics, Inc. | $4.6M | 16 | 506(b) | May 7, 2025 | 1 | direct |
| SANUWAVE Health, Inc. | $4.6M | 19 | 506(b) | Feb 5, 2024 | 1 | direct |
| Alpha Cognition Inc. | $4.5M | 22 | 506(b) | Oct 9, 2024 | 1 | direct |
| Infinity Bio, Inc. | $4.5M | 1 | 506(b) | Jun 3, 2024 | 2 | direct |
| COURAGE THERAPEUTICS, INC. | $4.5M | 14 | 506(b) | May 22, 2025 | 1 | direct |
| Vesica Health, Inc. | $4.5M | 12 | 506(b) | Mar 17, 2026 | 1 | direct |
| Remedium Bio Inc. | $4.4M | 26 | 506(b) | Aug 28, 2024 | 2 | direct |
| Phoreus Biotechnology, Inc. | $4.4M | 49 | 506(b) | Mar 13, 2026 | 3 | direct |
| MI:RNA Ltd | $4.4M | 57 | 506(b) | Nov 18, 2024 | 1 | direct |
| Cupron Performance Additives, Inc. | $4.4M | 12 | 506(b) | Feb 3, 2025 | 1 | direct |
| GelSana Therapeutics, Inc. | $4.4M | 33 | 506(b) | Oct 8, 2026 | 4 | direct |
| Greyledge Technologies, Inc. | $4.3M | 17 | 506(b) | May 9, 2023 | 3 | direct |
| Synchrony Medical Inc. | $4.3M | 12 | 506(b) | Mar 10, 2026 | 2 | direct |
| ValCor Cath Inc. | $4.3M | 52 | 506(b) | Aug 14, 2025 | 2 | direct |
| Synthetica Bio, Inc. | $4.3M | 16 | 506(b) | Aug 29, 2023 | 4 | direct |
| Genesis New Ventures, LLC | $4.2M | 19 | 506(b) | Apr 30, 2026 | 2 | direct |
| Io Therapeutics, Inc. | $4.2M | 19 | 506(b) | Aug 3, 2023 | 2 | direct |
| MAIA Biotechnology, Inc. | $4.1M | 43 | 506(b) | Mar 4, 2025 | 1 | direct |
| Galaxy Diagnostics, Inc. | $4.1M | 55 | 506(b) | Apr 22, 2025 | 1 | direct |
| Dermata Therapeutics, Inc. | $4.1M | 14 | 506(b) | Jan 7, 2026 | 1 | direct |
| Inmedix, Inc. | $4.0M | 34 | 506(c) | Oct 22, 2026 | 2 | direct |
| Endless Corp | $4.0M | 31 | 504 | Jan 30, 2025 | 2 | direct |
| Auxilium Biotechnologies Inc. | $3.9M | 16 | 506(b) | Dec 11, 2025 | 2 | direct |
| Cell Source, Inc. | $3.9M | 48 | 506(b) | Oct 6, 2023 | 1 | direct |
| CRISPRQC INC. | $3.9M | 14 | 506(b) | Apr 2, 2025 | 3 | direct |
| Resilient Biotics, Inc. | $3.9M | 6 | 506(b) | Dec 12, 2024 | 3 | direct |
| Reglagene, Inc. | $3.8M | 22 | 506(b) | Nov 21, 2023 | 3 | direct |
| Sift Biosciences, Inc. | $3.8M | 15 | 506(b) | Dec 22, 2025 | 1 | direct |
| Cerecin Inc. | $3.7M | 10 | 506(b) | Jun 25, 2024 | 1 | direct |
| JelliSee Ophthalmics Inc. | $3.7M | 34 | 506(b) | Apr 30, 2024 | 2 | direct |
| Certis Oncology Solutions, Inc. | $3.7M | 24 | 506(b) | Nov 17, 2023 | 1 | direct |
| Illuminare Biotechnologies Inc | $3.6M | 42 | 506(b) | Jun 4, 2026 | 1 | direct |
| ROC Holdings SPV II, LP | $3.6M | 16 | 506(b) | Aug 21, 2025 | 1 | direct |
| Porosome Therapeutics, Inc. | $3.6M | 7 | 506(b) | Mar 24, 2026 | 4 | direct |
| Long Bridge Medical, Inc. | $3.6M | 33 | 506(b) | Nov 3, 2023 | 1 | direct |
| Silexion Therapeutics Corp | $3.6M | 11 | 506(b) | Aug 11, 2025 | 1 | direct |
| Comera Life Sciences Holdings, Inc. | $3.6M | 14 | 506(b) | Jan 12, 2023 | 1 | direct |
| TETmedical, Inc. | $3.5M | 45 | 506(b) | Jun 24, 2026 | 1 | direct |
| Sower Solas I Sidecar III, LLC | $3.5M | 23 | 506(b) | Aug 12, 2025 | 1 | direct |
| GPN VACCINES, INC. | $3.5M | 63 | 506(b) | Jan 28, 2026 | 1 | direct |
| Red Sky Health Corp | $3.5M | 90 | 506(b) | May 2, 2025 | 1 | direct |
| FORAY bioscience, Inc. | $3.4M | 10 | 506(b) | Mar 14, 2024 | 1 | direct |
| Vicora, Inc. | $3.4M | 55 | 506(b) | Oct 20, 2025 | 1 | direct |
| Pacific Diabetes Technologies, Inc. | $3.4M | 15 | 506(b) | Nov 17, 2025 | 2 | direct |
| Autology, Inc. | $3.4M | 12 | 506(b) | Sep 30, 2026 | 1 | direct |
| LifeBridge Innovations, PBC | $3.4M | 64 | 506(c) | Jul 14, 2026 | 2 | direct |
| Xenon Ophthalmics Inc | $3.3M | 20 | 506(b) | Oct 6, 2026 | 3 | direct |
| AIM ImmunoTech Inc. | $3.3M | 1 | 506(b) | Feb 21, 2024 | 2 | direct |
| Intrommune Therapeutics, Inc. | $3.3M | 15 | 506(b) | Jan 22, 2024 | 1 | direct |
| Bodark Investment Group LP | $3.3M | 13 | 506(b) | Jun 23, 2025 | 1 | direct |
| Voltron Therapeutics, Inc. | $3.2M | 63 | 506(b) | Nov 9, 2023 | 2 | direct |
| Autoimmunity Biologic Solutions Inc. | $3.2M | 15 | 506(b) | May 6, 2026 | 2 | direct |
| Solenic Medical, Inc. | $3.2M | 17 | 506(b) | Mar 15, 2024 | 1 | direct |
| Medicovestor, Inc. | $3.2M | 60 | 506(b) | Dec 5, 2025 | 1 | direct |
| 3X Genetics Inc. | $3.2M | 52 | 506(b) | Mar 25, 2026 | 1 | direct |
| Bone Health Technologies, Inc. | $3.2M | 22 | 506(b) | May 9, 2023 | 1 | direct |
| Circular Genomics Inc. | $3.1M | 7 | 506(b) | Mar 9, 2023 | 2 | direct |
| Oral Genome Corp. | $3.1M | 37 | 506(b) | Jan 31, 2025 | 1 | direct |
| Fulmer Instruments, Inc. | $3.1M | 25 | 506(b) | Oct 16, 2024 | 1 | direct |
| SightStream Biotherapeutics, Inc. | $3.1M | 21 | 506(b) | Jun 12, 2023 | 3 | direct |
| Hepion Pharmaceuticals, Inc. | $3.1M | 33 | 506(b) | Aug 5, 2026 | 1 | direct |
| PanTher Therapeutics, Inc. | $3.0M | 26 | 506(b) | Apr 3, 2025 | 1 | direct |
| Flagship Biosciences, Inc. | $3.0M | 3 | 506(b) | Feb 21, 2024 | 2 | direct |
| iOncologi, Inc. | $3.0M | 17 | 506(b) | Mar 5, 2025 | 1 | direct |
| XiltriX North America, LLC | $3.0M | 20 | 506(b) | Aug 26, 2026 | 1 | direct |
| Cellphire, Inc. | $3.0M | 19 | 506(b) | Dec 11, 2025 | 1 | direct |
| Bio-AI Health Inc. | $3.0M | 1 | 506(b) | Jan 29, 2024 | 2 | direct |
| Aevumed Inc. | $3.0M | 36 | 506(b) | Jun 12, 2025 | 1 | direct |
| Auxilium Health, Inc. | $3.0M | 13 | 506(b) | May 15, 2026 | 1 | direct |
| Amplified Sciences, Inc. | $3.0M | 41 | 506(b) | Feb 20, 2026 | 2 | direct |
| Mitotherapeutix, LLC | $3.0M | 5 | 506(b) | May 22, 2025 | 3 | direct |
| Hypercell Technologies Inc. | $3.0M | 14 | 506(b) | Oct 14, 2026 | 1 | direct |
| RevivBio Inc. | $3.0M | 11 | 506(b) | Jan 16, 2024 | 1 | direct |
| Aspira Women's Health Inc. | $3.0M | 19 | 506(b) | Sep 18, 2025 | 1 | direct |
| Resolute Science, Inc. | $2.9M | 25 | 506(b) | Apr 3, 2026 | 2 | direct |
| Optimeos Life Sciences, Inc. | $2.9M | 5 | 506(b) | Nov 26, 2024 | 2 | direct |
| PhotonPharma, Inc. | $2.9M | 8 | 506(b) | Aug 29, 2023 | 2 | direct |
| Trinity Nuclein Rd III QP Investors LLC | $2.9M | 36 | 506(b) | Dec 15, 2023 | 1 | direct |
| Virtuoso Surgical, Inc. | $2.9M | 36 | 506(b) | May 11, 2026 | 1 | direct |
| Peytant Solutions, Inc. | $2.9M | 19 | 506(b) | Jan 10, 2025 | 3 | direct |
| Evofem Biosciences, Inc. | $2.9M | 14 | 506(b) | Oct 11, 2023 | 1 | direct |
| NovaDerm Aid Fund XII L.L.C. | $2.9M | 21 | 506(b) | Apr 17, 2023 | 1 | direct |
| EyeMacular Regeneration, Inc. | $2.9M | 14 | 506(b) | Sep 25, 2026 | 3 | direct |
| OrisDx Inc. | $2.8M | 25 | 506(b) | Jul 16, 2025 | 1 | direct |
| Sinopia Biosciences, Inc. | $2.8M | 35 | 506(b) | Jul 16, 2026 | 1 | direct |
| Cellebration Life Sciences, Inc. | $2.8M | 63 | 506(c) | Aug 21, 2023 | 4 | direct |
| Recourse Biologics, Inc. | $2.8M | 14 | 506(b) | Oct 8, 2024 | 1 | direct |
| Soricimed Biopharma Inc. | $2.8M | 45 | 506(c) | Jan 19, 2023 | 2 | direct |
| Visgenx, Inc. | $2.8M | 17 | 506(b) | Jun 14, 2023 | 1 | direct |
| inSoma Bio, Inc. | $2.7M | 16 | 506(b) | May 6, 2024 | 3 | direct |
| InnovoTEX Inc. | $2.7M | 21 | 506(b) | Aug 18, 2026 | 2 | direct |
| Maxymune Therapeutics, Inc. | $2.7M | 15 | 506(b) | Jun 3, 2026 | 2 | direct |
| TOMI Environmental Solutions, Inc. | $2.6M | 28 | 506(b) | Nov 28, 2023 | 1 | direct |
| Scalpel Ventures, LLC | $2.6M | 43 | 506(c) | May 6, 2026 | 4 | direct |
| One Health Group, Inc. | $2.6M | 8 | 506(b) | May 24, 2024 | 4 | direct |
| Healthcare Integrated Technologies Inc. | $2.6M | 20 | 506(b) | Nov 4, 2024 | 1 | direct |
| Urica Therapeutics, Inc. | $2.5M | 26 | 506(b) | Jan 5, 2023 | 1 | direct |
| AecorBio Inc. | $2.5M | 20 | 506(b) | Nov 12, 2025 | 1 | direct |
| HYDROCISION INC | $2.5M | 12 | 506(b) | Apr 1, 2025 | 1 | direct |
| Xenagos Bio, Inc. | $2.5M | 23 | 506(b) | May 15, 2026 | 1 | direct |
